VIVO Financial Facts

EFFECT OF DILUTIVE STOCK OPTIONS: -756K
Net Sales: 47M
See Full Income Statement

Other assets: 353K
Accounts payable: -14.86M
See Full Balance Sheet

Meridian Bioscience Inc. (VIVO) Earnings

  |   Expand Research on VIVO
Next EPS Date 8/5/22 *Est. EPS Growth Rate +19.6% *Last Qtr.
Average EPS % Beat Rate +45.3% Revenue Growth Rate +30.4% *Last Qtr.
Average % Move 1-Wk after EPS +4.2% Normal Earnings Time Before Open
Date  Qtr EPS Cons. Surprise Revs Cons. Gd. 1-Week % 1-Day % Details
5/6/22 Q222 $0.67$0.32 +$0.35$111.2M$83.29M = Details
2/4/22 Q122 $0.35$0.25 +$0.10$88.3M$70.29M = Details
11/12/21 Q421 $0.23$0.20 +$0.03$76.2M$68.4M = Details
5/7/21 Q221 $0.56$0.48 +$0.08$85.3M$84.5M = Details
11/13/20 Q420 $0.19$0.14 +$0.05$64.2M$59.6M = Details
2/7/20 Q120 $0.10$0.06 +$0.04$47.4M$48.7M = Details
11/7/19 Q419 $0.13$0.09 +$0.04$50.8M$50.59M = Details
7/30/19 Q319 $0.16$0.09 +$0.07$48.4M$49.81M = Details